ClinicalTrials.gg
Enrolling by invitationNCT03007589Updated May 15, 2025

Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics

An interventional study of otc sunscreens and sun protection fabrics in Sunburn, Sun Damaged Skin and Overexposure to Sun Rays, sponsored by Sun Protection Foundation. Enrolling by invitation at 5 sites in 3 countries. Open to participants aged 15 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Sun Protection Foundation · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Apr 2014, registered Dec 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
15 Years to 90 Years
Sex
All
01

Study summary

The purpose of this study is to assess how human skin reacts and how sunscreens and sun protection fabrics protect in natural sunlight compared to their labeled claims, indoor testing methods (existing or modified) and instructions.

Read the detailed description

To evaluate the difference in the level of erythema and persistent pigment darkening sun protection following a single period of natural sunlight exposure or laboratory solar simulator exposure afforded by application of sunscreens, use of fabrics, and use of pass through glass filters.

02

Conditions studied

  • Sunburn
  • Sun Damaged Skin
  • Overexposure to Sun Rays

Browse trials for

Keywords

  • erythema
  • persistent pigment darkening
  • sunburn
  • suntan
03

In context

Sunburn

29 studies on the registry are indexed under Sunburn; 2 are open to participants now.

This study's planned enrollment of 200 is above the median of 54 across 26 interventional studies indexed under Sunburn.

Browse Sunburn studies →

Lead sponsor

This is the only study on the registry with Sun Protection Foundation as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fitzpatrick Type I, II, III, IV or V type skin.
  2. Must be able to be exposed to natural sunlight for up to 4 hours in a prone position
  3. Able to read, write, speak and understand the English language.
  4. Has personally read, signed, and dated the Form (including HIPAA disclosure) and Photograph Release
  5. Generally in good health based on medical history reported by the subject
  6. Healthy male or female subjects with no history or evidence of medical disorder, as determined from a brief medical history interview.
  7. Willing and able to follow the study instructions, including:

    • Remain outdoors exposed to the sun or in the laboratory for up to 4 hours on Day 1 during the study with exposed skin on back protected by sunscreens and fabrics
    • Apply the specific sunscreens and fabrics to designated sites on the back and lie motionless.
    • No visual signs of recent sun exposure to the back.
    • No sunscreens or lotions recently used on the back.
    • Attend scheduled visits and intend to successfully complete the study
    • Stay out of the sun or stay indoors from sun exposure until after observation on Day 2.
    • Women are discouraged from using a bra that applies pressure to the skin site areas that may make it difficult to assess erythema or PPD on Day 2.
    • Refrain from using other sunscreen products or tanning bed use during the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with known allergies or sensitivities to sunscreens or any ingredient contained in the test products or common topical skincare products, including adhesives.
  2. Perceptible erythema, PPD on the back as determined by the PI or designee.
  3. Women known to be pregnant or nursing.
  4. Individuals with any disease or condition of the skin (e.g., active [i.e. flaring] eczema or psoriasis, skin cancer, atypical nevus, polymorphic light eruption (PMLE), porphyria, systemic lupus erythematous (SLE), xeroderma pigmentosa (XP)) that could interfere with the study or increase risk to the subject.
  5. Individuals with self-reported UNCONTROLLED metabolic conditions, such as diabetes, hypertension, hyper/hypothyroidism, hypercholesterolemia
  6. Subjects who are taking medication for chronic conditions that may make a subject more sun sensitive (e.g., Tetracyclines, antifungals, certain diuretics, etc.)
  7. Skin diseases on tested sites (e.g., photosensitivity disorders, etc.), which may influence the outcome of the study
  8. An individual who has any condition which in the PI's judgment makes the candidate an inappropriate subject for study participation
  9. Individuals with a condition or situation which, in the PI's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
  10. Individual viewed by the PI as not being able to complete the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Location

    Location and Intensity of Exposure to Sunlight otc sunscreens sun protection fabrics optical filters

    Drug: otc sunscreens · Other: sun protection fabrics · Other: Optical Filters

  • Other
    Single Duration or SPF Test

    Single exposure of interventions or multiple exposures of interventions (SPF or PPD-PF tests) otc sunscreens sun protection fabrics optical filters

    Drug: otc sunscreens · Other: sun protection fabrics · Other: Optical Filters

Interventions

  • Drugotc sunscreens

    Sunscreens of various SPF levels and ingredients

    Also known as: 30 SPF Broad Spectrum Sunscreen, 40 SPF Broad Spectrum Sunscreen, 45 SPF Broad Spectrum Sunscreen, 50 SPF Broad Spectrum Sunscreen, 60 SPF Broad Spectrum Sunscreen, 100 SPF Broad Spectrum Sunscreen, 110 SPF Broad Spectrum Sunscreen, Sunscreen Standard P2 15 SPF, Sunscreen Standard S2 12 UVA-PF, Sunscreen Standard P1 4 SPF, 70 SPF Broad Spectrum Sunscreen, 85 SPF Broad Spectrum Sunscreen, Reference Standard Sunscreens at various SPF levels

  • Othersun protection fabrics

    fabrics

    Also known as: 100+ SPF Broad Spectrum Fabric Solumbra, 30+ SPF Broad Spectrum Fabric Solumbra

  • OtherOptical Filters

    Optical band pass or long pass filters or surfaces/mirrors used in solar simulators

    Also known as: Pass Through Glass

06

What researchers measure

Primary outcomes

  1. Erythema

    • Erythema was assessed using a scale of 0 = no perceptible sun induced skin reaction, 1 = perceptible erythema but spotty or without clear borders (\<1 MED); 2 = minimal erythema over the entire site with distinct borders (1 MED reaction); 3 = more than minimal; 4 = a serious erythema; and 5 = edema and blisters. Determination made by blinded evaluator on-site or using chroma-meter and photographs.

    Time frame: 16-24 hours post exposure to natural sunlight

  2. Persistent Pigment Darkening (PPD)

    Persistent Pigment Darkening was assessed using a scale of 0 = no perceptible sun induced skin reaction, 1 = perceptible but spotty or without clear borders (\<1 MPPDD); 2 = minimal PPD over the entire site with distinct borders (1 MPPDD reaction); 3 = more than minimal; 4 = a serious erythema; and 5 = edema and blisters Determination made by blinded evaluator on-site or using chroma-meter and photographs.

    Time frame: 16-24 hours post exposure to natural sunlight

07

Study locations

5 sites
  • Sun Protection Foundation
    San Diego, California 98108, United States
  • Sun Protection Foundation
    Waimea, Hawaii 98108, United States
  • Sun Protection Foundation
    Seattle, Washington 98108, United States
  • Sun Protection Foundation
    Santiago, Chile
  • Sun Protection Foundation
    Arequipa, Peru
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2014 (actual). Primary completion is estimated for Jan 2040, 309 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2016
First posted
Jan 2, 2017
StartActual
Apr 2014
Primary completionEst.
Jan 2040
CompletionEst.
Jan 2040
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03007589
Lead sponsor
Sun Protection Foundation
Responsible party
Sponsor
First posted
Jan 2, 2017
Start date
Apr 2014
Primary completion
Jan 2040 (estimated)
Completion
Jan 2040 (estimated)
Last update
May 15, 2025

Study contacts

Shaun Hughes, MBA
principal investigator · Sun Protection Foundation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion